The Pharmaceutical Market in Egypt

The report analyzes the macroeconomic and political situation in Egypt. It covers the healthcare system, and major causes of disease and mortality. It focuses on pharmaceuticals, including their regulation, pricing, intellectual property rights, and counterfeits. It examines pharmaceutical sales, manufacturing, trade, and major multinationals and local companies.

Features and benefits

• Understand the key pharmaceutical market characteristics, including total market size, growth drivers and resistors and overall market attractiveness.
• Evaluate the latest political situation and healthcare reforms and how they impact the pharmaceutical market.
• Develop an understanding of the intellectual property and regulatory environment and how these can affect your product launch strategy.
• Gain insight into controversial pricing issues, which have held back prices and hit profits.
• Assess the major domestic and overseas pharma companies active in Egypt.

Highlights

The Egyptian pharmaceutical market is focused on generics. Per capita spending is low, but the large population means overall sales are worth around $3bn. Out-of-pocket expenditure accounts for around 75% of pharmaceutical sales. In the long term, increasing affluence and universal health insurance will boost sales.

Historically, intellectual property rights were not enforced, and firms were able to register generics/copies using data from the originator companies. Despite some changes, Egypt is on the Watch List of the US Trade Representative due to inadequate enforcement. This means that companies have been slow to introduce new products.

Egypt has certain key differences from many other markets. For example, the data protection period for drugs is five years from when the registration application is filed, rather than from the date of market authorization.

Your key questions answered

• How is the political situation affecting pharmaceutical sales?
• What is the nature of research environment in Egpyt?
• How are the healthcare reforms going to affect the pharmaceutical market?
• How strictly are intellectual property rights enforced in Egypt?
• What are the major causes of morbidity and mortality in Egypt?

Table Of contents

About the author
Disclaimer

EXECUTIVE SUMMARY
The macroeconomic climate
The healthcare system and health
Regulation
The pharmaceutical market

The macroeconomic climate
Summary
Introduction
Country overview
Economic situation
Political upheaval and effect on economy

The healthcare system and health
Summary
Introduction
Healthcare expenditure
The healthcare system
Life expectancy
Causes of death
Non-communicable diseases
Communicable diseases
Other causes of death
Disease burden
Non-communicable diseases
Communicable diseases
Other diseases and injuries

Regulation
Summary
Introduction
Regulation
Pricing
IPR
Counterfeit pharmaceuticals

The pharmaceutical market
Summary
Introduction
Pharmaceutical sales
Market forecast
Manufacturing
Trade
Imports
Exports
Distribution network
Major companies
MNCs
Regional companies
Local companies

Appendix
Scope
Methodology
Glossary/Abbreviations
Bibliography/References

List Of Tables

Table: Ease of doing business in Egypt ranked vs. rest of world, 2011
Table: Healthcare: examples of finance sources, financing agents & providers
Table: Pharmaceutical sales in Egypt, 1995–2009
Table: Per capita spending on pharmaceuticals in Egypt, 1995–2009
Table: Egypt pharmaceutical trade in $m, 2008–10
Table: HoldiPharma’s subsidiaries, percentage stake, and number of employees
Table: HoldiPharma Group sales and income, 2010–11

List Of Figures

Figure: Population of MENA countries, 2010
Figure: GNI ($bn) for top ranked MENA countries, 2009
Figure: GNI ($000) per capita for top ranked MENA countries, 2009
Figure: Egypt’s annual growth in GDP (%), 1980–2010
Figure: Healthcare expenditure for selected countries, 2009
Figure: Public health expenditure as % of total health expenditure, 2009
Figure: OOP expenditure as % of private health expenditure, 2009
Figure: Financing sources of Egyptian healthcare, 2007–08
Figure: Financing agents of Egyptian healthcare, 2007–08
Figure: Providers of Egyptian healthcare, 2007–08
Figure: Life expectancy at birth for MENA countries, 2009
Figure: Egyptian mortality rates per 1,000 live births, 1980–2010
Figure: Egypt mortality rates for the under-fives per 1,000 live births
Figure: Egyptian causes of death, 2008
Figure: Non-communicable diseases causes of death, 2008
Figure: Main causes of cardiovascular deaths, 2008
Figure: Main causes of malignant neoplasm deaths, 2008
Figure: Communicable diseases causes of death, 2008
Figure: Egypt’s overall burden of disease by DALYs, 2004
Figure: Egypt’s non-communicable diseases by DALYs, 2004
Figure: Selected non-communicable diseases by DALYs, 2004
Figure: Egypt’s communicable diseases by DALYs, 2004
Figure: Work flow for authorization of imported branded and generic drugs
Figure: Types of products registered in Egypt by source, 2011
Figure: Registrations for products manufactured overseas by country, 2011
Figure: Pharmaceutical sales in Egypt, 1995–2009
Figure: Per capita spending on pharmaceuticals in Egypt, 1995–2009
Figure: Spending on pharmaceuticals by purchaser, 2007–08
Figure: MoH spending on healthcare, 2007–08
Figure: Household OOP spending on healthcare, 2007–08
Figure: Egypt pharmaceutical market forecast ($bn), 2012–17
Figure: Imports of medicament mixtures in dosage or packaged for retail, 2010
Figure: Exports of medicament mixtures in dosage or packaged for retail, 2010
Figure: Pharmaceuticals registered and manufactured by MNCs in Egypt, 2011